- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Laguna Hills Today
By the People, for the People
Adagio Medical Receives FDA Approval for Next-Gen Ablation System
The company's vCLAS® Ventricular Ablation System will undergo clinical investigation.
Apr. 8, 2026 at 5:45pm
Got story updates? Submit your updates here. ›
Adagio Medical's new vCLAS system aims to improve the precision and control of cardiac ablation procedures, offering hope for patients with life-threatening heart rhythm disorders.Laguna Hills TodayAdagio Medical, a leading innovator in catheter ablation technologies, has received Investigational Device Exemption (IDE) approval from the FDA to investigate its next-generation vCLAS® Ventricular Ablation System. The system is designed for the treatment of ventricular arrhythmias.
Why it matters
Adagio's vCLAS system represents an important advancement in cardiac ablation technology, which is used to treat life-threatening heart rhythm disorders. The IDE approval allows the company to conduct clinical trials to evaluate the safety and efficacy of the system, potentially leading to a new treatment option for patients.
The details
The vCLAS system is Adagio's latest innovation in catheter ablation, a minimally invasive procedure used to treat abnormal heart rhythms. The system is designed to improve upon existing technologies by offering enhanced precision and control during the ablation process.
- Adagio Medical received IDE approval from the FDA on April 8, 2026.
The players
Adagio Medical Holdings, Inc.
A leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias.
What’s next
With the IDE approval, Adagio will now begin the process of enrolling patients in a clinical trial to evaluate the safety and efficacy of the vCLAS Ventricular Ablation System.
The takeaway
Adagio's next-generation vCLAS system represents an important advancement in cardiac ablation technology, which could provide a new treatment option for patients with life-threatening heart rhythm disorders.
